Demsky joined the University of Michigan Rogel Cancer Center communications team in 2019. Prior to that he served as director of communications for the University of Michigan's Life Sciences Institute and science editor for Medicine at Michigan Magazine. Contact: idemsky@med.umich.edu
The analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.
The U-M-led development and validation of a staging system for non-metastatic prostate cancer could help doctors and patients assess treatment options, as well as improve clinical trials.
Researchers have demonstrated that a new liquid biopsy approach overcomes traditional barriers to quickly and efficiently diagnose and monitor high-grade gliomas.
This phase 2 trial also identified a subset of patients with specific mutations who may see the most benefit from the drug.
A U-M Rogel Cancer study provides an updated, more comprehensive look at trends for this rare, aggressive form of breast cancer over the last four decades.
The new approach could help doctors to separate aggressive stage 0 breast cancer from non-aggressive forms, sparing some women unnecessary mastectomies.
